AAN 2022 | Emerging biomarkers in MS: the value of serum NfL

Augusto Miravalle, MD, FAAN, University of Colorado School of Medicine, Aurora, CO, discusses emerging biomarkers of disease response and prognosis in multiple sclerosis (MS) and how these biomarkers may aid treatment decision-making. Dr Miravalle first emphasizes the value of using serum neurofilament light chain protein (NfL) to better understand inflammatory activity and predict patient response to therapies and further highlights the importance of combining various biomarkers and using more advanced MRI techniques. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.